CML blasts have constitutive p65 (RelA NF-κB) transcriptional activity, and NF-κB may be a potential target for molecular therapies in CML that may also be effective against CML cells with Bcr-Abl-T315I. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.